Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Placenta-specific protein 1 (PLAC1)
- Target
- PLAC1
- Molecular classification
- Cell surface protein, Cancer/testis antigen, Adhesion molecule (via zona pellucida-like domain), Secreted protein with truncated ZP (zona pellucida) domain
01
Overview
Placenta-specific protein 1 (PLAC1) is a 212-amino acid, type II membrane-associated protein that localizes to the cell surface and extracellular matrix of placental trophoblasts. It features a truncated zona pellucida domain homologous to sperm receptor ZP3, suggesting an adhesion and signaling role. PLAC1 is critically involved in the establishment and maintenance of the placenta and is re-expressed in multiple human cancers, where it enhances cell motility, invasion, and proliferation via PI3K/AKT pathway activation (mediated by its interaction with FGF7 and FGFR2IIIb). Aberrant PLAC1 expression is implicated in gestational disorders and is under investigation as a biomarker and potential immunotherapy target for cancer.
- Other names
- PLAC1CT92OOSP2LOOSP2Bplacenta enriched 1placenta specific 1cancer/testis antigen 92
02
Mechanism of action
For immunotherapy: Activation of cytotoxic T cells or antibody responses targeting PLAC1-positive cancer cells; For possible inhibitors: Blockade of PLAC1 interaction with FGF7/FGFR2IIIb to inhibit AKT-mediated tumor cell proliferation
03
Biological functions
Placental development and maintenanceCell proliferationCell migration and invasionSignal transduction (involved with PI3K/AKT pathway via interaction with FGF7/FGFR2IIIb)Immune response (antigen presentation in cancer)
04
Disease associations
Cancer (highly expressed in diverse tumors, e.g., breast, prostate, placental choriocarcinoma)Gestational disorders (abnormal expression linked to preeclampsia, intrauterine growth restriction, premature birth, implantation failure, infertility)
05
Safety considerations
Potential impact on placental function and gestation due to PLAC1’s essential role in placental developmentRisk of off-target effects in pregnancy, infertility, or fetal growth if targeted therapeuticallyImmunogenicity in normal placenta-bearing women
06
Interacting drugs
Direct interacting drugs are currently not approved or reported in clinical use; experimental immunotherapies may be developed targeting PLAC1 as a tumor antigen
07
Biomarkers
PLAC1 protein/mRNA as a diagnostic marker for certain cancers (breast, prostate, placenta-derived tumors)May be used as an assay biomarker for gestational diseases (e.g., preeclampsia, IUGR)
Beyond the preview
Go deeper on Placenta-specific protein 1 (PLAC1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Placenta-specific protein 1 (PLAC1).